This study involved 78 participants taking 150 mg of Ibandronate once a month for the investigation
of the drug efficacy and safety. Ibandronate had a strong antiresorptive action that decreased 67.9 per cent of
bone resorption. The total cases of unwanted effect were 21 that showed the common adverse events like other
bisphosphonate. The most common events were flu-like symptom (8.75%) and dyspepsia (7.5%) which occurred
at the first tablet. Most participants subsided after the following months, but only one case persisted in these
symptoms through the study period while the others had a myalgia, diarrhea and burning of epigastric in
percent of 6.25, 2.5, 1.25 respectively. Ibandronate (150mg) showed the strong antiresorptive effect and good
compliance for taking once a month.

Keywords: Ibandronate